[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603753":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":23,"studyPopulation":23,"armGroups":34,"interventions":50,"overallOfficials":23,"centralContacts":71,"locations":79,"responsibleParty":143,"collaborators":23,"id":145,"slug":146,"hasResults":147,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":23,"eligibilityCriteria":151,"healthyVolunteers":147,"sex":152,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":23,"studyType":158,"phases":159,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":82,"whyStopped":23,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},{"fullName":5,"class":6},"Novartis","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)","Incidence of AEs and SAEs by treatment group, including changes in vital signs, laboratory measures, neurological examinations and electrophysiology measures qualifying and reported as AEs.","From baseline up to day 140",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"EDK060 Plasma PK parameters - Cmax","The maximum (peak) observed EDK060 plasma concentration after single dose administration (mass x volume-1)",{"measure":18,"description":19,"timeFrame":12},"EDK060 Plasma PK parameters - Tmax","The time to reach maximum (peak) plasma, EDK060 concentration after single dose administration (time)",{"measure":21,"description":22,"timeFrame":12},"EDK060 Plasma PK parameters - AUClast","The area under the concentration-time curve of EDK060 from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)",null,{"allocation":25,"interventionModel":26,"interventionModelDescription":23,"primaryPurpose":27,"observationalModel":23,"timePerspective":23,"maskingInfo":28},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":29,"maskingDescription":23,"whoMasked":30},"TRIPLE",[31,32,33],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[35,44],{"label":36,"type":37,"description":38,"interventionNames":39},"EDK060","EXPERIMENTAL","Doses A; B; C; D",[40,41,42,43],"Drug: EDK060, dose A","Drug: EDK060, dose B","Drug: EDK060, dose C","Drug: EDK060, dose D",{"label":45,"type":46,"description":47,"interventionNames":48},"Placebo","PLACEBO_COMPARATOR","Matching placebo",[49],"Other: Placebo",[51,56,60,64,68],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":23},"DRUG","EDK060, dose A","EDK060, dose A, Single dose, IV infusion",[36],{"type":52,"name":57,"description":58,"armGroupLabels":59,"otherNames":23},"EDK060, dose B","EDK060, dose B, Single dose, IV infusion",[36],{"type":52,"name":61,"description":62,"armGroupLabels":63,"otherNames":23},"EDK060, dose C","EDK060, dose C, Single dose, IV infusion",[36],{"type":52,"name":65,"description":66,"armGroupLabels":67,"otherNames":23},"EDK060, dose D","EDK060, dose D, Single dose, IV infusion",[36],{"type":69,"name":45,"description":45,"armGroupLabels":70,"otherNames":23},"OTHER",[45],[72,77],{"name":73,"role":74,"phone":75,"phoneExt":23,"email":76},"Novartis Pharmaceuticals","CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":73,"role":74,"phone":78,"phoneExt":23,"email":23},"+41613241111",[80,103,113,126],{"facility":81,"status":82,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":93,"contacts":94},"The Ottawa Hospital","RECRUITING","Ottawa","Ontario","K1H 8L6","Canada","CA",{"type":89,"coordinates":90},"Point",[91,92],-75.69812,45.41117,{"lat":92,"lon":91},[95,100],{"name":96,"role":74,"phone":97,"phoneExt":98,"email":99},"Jessica Belanger","613-798-5555","19627","jessicabelanger@ohri.ca",{"name":101,"role":102,"phone":23,"phoneExt":23,"email":23},"Alberto Aleman","PRINCIPAL_INVESTIGATOR",{"facility":104,"status":82,"city":105,"state":106,"zip":107,"country":86,"countryCode":87,"cosmosGeoPoint":108,"geoPoint":112,"contacts":23},"Novartis Investigative Site","Montreal","Quebec","H2X 1R9",{"type":89,"coordinates":109},[110,111],-73.58781,45.50884,{"lat":111,"lon":110},{"facility":114,"status":82,"city":105,"state":106,"zip":115,"country":86,"countryCode":87,"cosmosGeoPoint":116,"geoPoint":118,"contacts":119},"Montreal Neurological Institute","H3A 2B4",{"type":89,"coordinates":117},[110,111],{"lat":111,"lon":110},[120,124],{"name":121,"role":74,"phone":122,"phoneExt":23,"email":123},"Julien Kridelka","514 398 78 58","Julien.kridelka@mcgill.ca",{"name":125,"role":102,"phone":23,"phoneExt":23,"email":23},"Rami Massie",{"facility":127,"status":82,"city":128,"state":106,"zip":129,"country":86,"countryCode":87,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"CIUSS de l´Estrie-CHUS- Hôpital Fleurimont","Sherbrooke","J1H 5N4",{"type":89,"coordinates":131},[132,133],-71.89908,45.40008,{"lat":133,"lon":132},[136,141],{"name":137,"role":74,"phone":138,"phoneExt":139,"email":140},"Caroline Cayer","1-819-346-1110","13920","caroline.cayer.ciussse-chus@ssss.gouv.qc.ca",{"name":142,"role":102,"phone":23,"phoneExt":23,"email":23},"Marie-France Rioux",{"type":144,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100603753","phase-1-a-first-in-human-study-to-assess-the-safety-tolerability-and-pharmacokinetics-of-edk060-in-adults-with-cmt1a-100603753",false,"NCT07140614","A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.","A First-in-human, Multi-center, Randomized, Participant- and Investigator-blinded, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With Charcot-Marie Tooth Type 1A (CMT1A).","Inclusion Criteria:\n\n* Provide written informed consent before any assessment is performed.\n* Be male or female and 18 to 60 (inclusive) years of age at the time of screening.\n* Participant must have a clinical diagnosis of Charcot-Marie-Tooth Disease Type 1A (CMT1A) including verified documentation of genetic testing showing duplication of the PMP22 gene by an accredited\u002Fcertified laboratory (according to local regulations)\n* Have detectable upper extremity nerve conduction velocities (sensory and\u002For motor) in at least one extremity at screening.\n* CMTNSv2R score \\>2 and ≤20 in at least one assessment, confirmed either at the baseline visit or documented in the medical record within the 6 months prior to baseline.\n* Muscle weakness evidenced by foot dorsiflexion MRC grade \\\u003C5 in at least one limb, confirmed either at screening assessment or documented in the medical record within the 6 months prior to screening.\n\nExclusion Criteria\n\n* Unable to communicate well with the investigator, to understand and comply with the visits and procedures of the study.\n* History of cardiac, renal, liver, hematological, immune system disorders.\n* Pregnant\u002Fnursing female participants. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for the duration of the follow-up period. Sexually active males unless they use a condom during intercourse.\n* Inability or unwillingness to provide serial skin biopsy samples.\n* Inability or unwillingness to undergo repeated venipuncture or in the opinion of the investigator, participant would be at an increased risk for adverse events related to these procedures.\n* Use of any drug intended to modify the course of CMT1A within 6 months from screening, including but not limited to: PTX-3003 (baclofen, sorbitol, and naltrexone in combination).\n* History of compression neuropathy within the last 6 months from screening and\u002For other conditions that can cause peripheral neuropathy, including but not limited to diabetes, chronic alcoholism, exposure to neurotoxic medications, exposure to environmental neurotoxins, traumatic nerve injury, thyroid disease, or infections.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years","60 Years",{"count":156,"type":157},28,"ESTIMATED","INTERVENTIONAL",[160],"PHASE1","The purpose of this study is to characterize the safety, tolerability, and pharmacokinetics of EDK060 as compared to placebo in adult patients with CMT1A.",[163],"Charcot-Marie-Tooth Disease, Type 1A",[165],"CMT1A","2026-07-28",{"date":168,"type":169},"2026-07-29","ACTUAL",{"date":171,"type":169},"2025-09-30",{"date":173,"type":157},"2028-02-26",{"name":73,"class":6},4]